20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Absci Corp (ABSI) operates in the BIOTECHNOLOGY industry and is headquartered in Vancouver, United States with about 140 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, ABSI reported $3M in revenue and ($115M) in net income.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Interactive charts & full statements → Open the ABSI valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $2M | $3M | $5M | $6M | $6M | $5M | $5M | $2M |
| Gross Profit | ($4M) | ($9M) | ($58M) | ($42M) | ($53M) | ($40M) | ($7M) | $2M |
| Gross Margin % | -255.9% | -319.4% | -1277.6% | -731.9% | -925.0% | -832.4% | -139.5% | 100.0% |
| Operating Income (EBIT) | ($131M) | ($125M) | ($109M) | ($116M) | ($107M) | ($75M) | ($13M) | ($6M) |
| Operating Margin % | -8411.3% | -4454.2% | -2401.6% | -2020.2% | -1857.5% | -1573.4% | -278.3% | -304.1% |
| Net Income | ($121M) | ($115M) | ($103M) | ($111M) | ($105M) | ($101M) | ($14M) | ($7M) |
| Net Margin % | -7756.4% | -4113.7% | -2274.1% | -1933.7% | -1825.4% | -2111.2% | -300.3% | -319.6% |
| EBITDA | ($110M) | ($103M) | ($94M) | ($80M) | ($91M) | ($68M) | ($13M) | ($6M) |
| Earnings Per Share (EPS) | $-0.80 | $-0.84 | $-0.94 | $-1.20 | $-1.15 | $-1.09 | $-0.16 | $-0.07 |
| Shares Outstanding (M) | 157M | 137M | 110M | 92M | 91M | 93M | 92M | 92M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $1M | $0M | $1M | $1M | $1M | $2M |
| Gross Profit | $0M | ($3M) | ($2M) | $0M | ($20M) | ($15M) | ($16M) | ($2M) |
| Gross Margin % | 100.0% | -1168.8% | -335.1% | 100.0% | -3349.9% | -1288.0% | -2452.9% | -97.2% |
| Operating Income (EBIT) | ($34M) | ($31M) | ($36M) | ($30M) | ($31M) | ($28M) | ($30M) | ($29M) |
| Operating Margin % | -10741.5% | -14347.0% | -5560.3% | -7977.2% | -5293.9% | -2351.9% | -4477.3% | -1698.7% |
| Net Income | ($33M) | ($30M) | ($30M) | ($29M) | ($31M) | ($26M) | ($29M) | ($27M) |
| Net Margin % | -10443.4% | -13767.0% | -4548.0% | -7594.2% | -5155.0% | -2234.6% | -4358.4% | -1610.7% |
| EBITDA | ($30M) | ($27M) | ($27M) | ($26M) | ($27M) | ($23M) | ($25M) | ($24M) |
| Earnings Per Share (EPS) | $-0.21 | $-0.19 | $-0.20 | $-0.20 | $-0.24 | $-0.21 | $-0.25 | $-0.24 |
| Shares Outstanding (M) | 157M | 153M | 151M | 144M | 128M | 124M | 115M | 114M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($108M) | ($93M) | ($72M) | ($65M) | ($81M) | ($61M) | ($11M) | ($6M) |
| Capital Expenditures (CapEx) | $1M | $1M | $0M | $1M | $16M | $38M | $2M | $1M |
| Free Cash Flow (FCF) | ($109M) | ($94M) | ($73M) | ($65M) | ($98M) | ($99M) | ($13M) | ($7M) |
| FCF Margin % | -6994.2% | -3358.3% | -1605.8% | -1145.4% | -1696.8% | -2062.8% | -275.1% | -346.1% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($28M) | ($26M) | ($29M) | ($25M) | ($17M) | ($22M) | ($17M) | ($21M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $1M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($28M) | ($26M) | ($29M) | ($26M) | ($17M) | ($22M) | ($17M) | ($21M) |
| FCF Margin % | -8668.2% | -12249.8% | -4505.4% | -6876.5% | -2883.0% | -1854.4% | -2554.4% | -1221.6% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $269M | $216M | $214M | $217M | $321M | $426M | $89M | $19M |
| Cash & Cash Equivalents | $108M | $20M | $41M | $72M | $60M | $253M | $70M | $13M |
| Total Liabilities | $23M | $27M | $34M | $41M | $47M | $60M | $22M | $61M |
| Total Debt (Short + Long-Term) | $2M | $3M | $6M | $10M | $15M | $8M | $8M | $4M |
| Total Shareholders' Equity | $246M | $189M | $179M | $176M | $274M | $366M | $67M | ($41M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ABSI viewer.
About TickerBase · Data methodology & sources · Privacy · Terms